Beam Therapeutics Inc (BEAM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $24.95 (+1.14%), Market cap $3.33B, 52-week low–high $15.83 ~ $35.41.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE
Financial statements, price targets, institutional (13F) holdings and related news for Beam Therapeutics Inc are updated in real time on BlackAll Trade.
Beam Therapeutics Inc trades at $24.95 (+1.14%). Real-time quotes and charts are available on BlackAll Trade.
Beam Therapeutics Inc has a market cap of about $3.33B.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology